ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open.
Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10188147/fc37036c2f
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.
The conference call will also be available through live webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=rPb7Xp5V and is also available through the company’s website.
A webcast replay of the call will be available approximately one hour after the end of the call through August 14, 2024. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (toll) or via an international dial-in number at: https://services.choruscall.com/ccforms/replay.html. Please use the following replay code 9720210. The telephonic replay will be available until May 28, 2024.
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
| For press inquiries: | For investor inquiries: |
| Jules Abraham | Scott Gordon |
| for Alimera Sciences | for Alimera Sciences |
| 917-885-7378 | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$5.54 |
| Daily Volume: | 0 |
| Market Cap: | US$301.270M |
August 06, 2024 May 14, 2024 March 19, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
